Table 5.
Clinical cases reported in the literature discussing the off label uses of tildrakizumab.
| Case Report | Sample Size | Condition | Tildrakizumab dosage and regimen | Outcome | Adverse events |
|---|---|---|---|---|---|
| John and Sinclair (160) | 1 | Refractory pyoderma gangrenosum of the penis and polymyalgia rheumatica | Tildrakizumab 100 mg; weeks 0, 4, every 12 weeks thereafter | Re-epithelialisation of ulceration, complete resolution | None |
| Kok et al. (161) | 1 | Pyoderma gangrenosum, acne and hidradenitis suppurativa (PASH) | Tildrakizumab 100 mg; weeks 0, 4, the tildrakizumab 200 mg every 4 weeks thereafter | Clinical improvement, abscess and nodule count of 5 compared to 68 baseline, DLQI score of 19 compared to 26 baselines | None |
| Kok et al. (162) | 5 | Moderate- to-severe hidradenitis suppurativa | Tildrakizumab 100 mg; weeks 0, 4, the tildrakizumab 200 mg every 4 weeks thereafter | All patients demonstrated an improvement, mean reduction of 16.8 (P = 0.04) in abscess and nodule count; four patients had DLQI improvement, DLQI, mean difference = 8.0, P = 0.46; Three patients had reduction in VAS, mean difference = 1.2, P = 0.64 | None |
| Ismail et al. (163) | 1 | 15-year history of treatment-resistant lupus erythematosus tumidus | Tildrakizumab 100 mg, weeks 0, 4, and 16 | Improvements in facial plaques | None |
| Ismail and Sinclair (164) | 1 | 9-month history of biopsy-proven, severe erosive oral lichen planus | Tildrakizumab 100 mg, weeks 0, 4, and 16 | complete healing of erosions, with residual fine reticular striations | None |
| Kerkemeyer et al. (165) | 1 | 15-year history of pruritic lichenoid papules and plaques | Tildrakizumab 100 mg, weeks 0, 4, and 16 | Reduction in itch; significant improvement, near-complete clinical resolution after 3 doses | None |
| Jerjen et al. (166) | 1 | 3-month history of rapidly progressive vitiligo | Tildrakizumab 100 mg; weeks 0, 4, 12, then 3-month intervals | 55% reduction in Vitiligo Area Scoring Index, 90% repigmentation in affected areas | None |
| Ismail et al. (167) | 1 | Psoriatic nail dystrophy and psoriatic arthritis | Tildrakizumab 100 mg, weeks 0, 4, and 16 | Significant improvement; patient noticed reduced time for arthritic pain to ease in the morning | None |
| Kerkemeyer and Sinclair (168) | 10 | Alopecia areata | Tildrakizumab 100 mg, weeks 0, 4, and 16 | 2 patients had a partial response (16–99%); 8 patients had no response; 1 patient with- drew due to no response | Mild; Upper respiratory tract infection, acne |
| Trindade de Carvalho et al. (169) | 1 | Recalcitrant lichen planopilaris and frontal fibrosing alopecia | Tildrakizumab 100 mg; weeks 0, 4, every 12 weeks thereafter | Remission and clinical improvements maintained at 13 months | None |